期刊文献+

肝内胆管癌的流行病学特征及危险因素研究进展 被引量:11

Epidemiological characteristics and risk factors of intrahepatic cholangiocarcinoma
下载PDF
导出
摘要 与肝门部胆管癌和肝外胆管癌相比,肝内胆管癌是一种少见的胆管恶性肿瘤,它具有独特的临床病程和流行病学特征。全世界范围内,肝内胆管癌的发病率具有很大的地域性差异,且整体发病率呈上升趋势。尽管目前已经确定了几个危险因素,如胆道疾病、感染因素等等,但许多患者并无明确的危险因素。现将其流行病学及发病危险因素作一综述。 Intrahepatic cholangiocarcinoma(ICC) is a rare cholangiocarcinoma with a distinct clinical course and epidemiology from hilar and extrahepatic cholangiocarcinoma.The incidence of ICC remains a considerable amount of geographic variation worldwide.Besides,the overall incidence of this malignancy appears to be rising.Several risk factors have been identified,such as biliary tract disease,infectious causes and so on.Despite this,a substantial number of ICC patients do not have any identifiable risk factors.This article will briefly introduce the research progress of epidemiological characteristics and risk factors of intrahepatic cholangiocarcinoma.
作者 高博 赵海鹰 Gao Bo;Zhao Haiying(Department of General Surgery,the Fourth Affiliated Hospital of China Medical University,Liaoning Shenyang 110032,China)
出处 《现代肿瘤医学》 CAS 2020年第7期1214-1217,共4页 Journal of Modern Oncology
关键词 肝内胆管癌 流行病学 危险因素 intrahepatic cholangiocarcinoma epidemiology risk factor
  • 相关文献

参考文献5

二级参考文献39

  • 1Yan-Ming Zhou, Lu Cao, Bin Li, Xiu-Zhong Zhang, Zheng-Feng Yin Department of Hepato-Biliary-Pancreato-Vascular Surgery, First Affiliated Hospital of Xiamen University, Xiamen 361003, China,Department of Molecular Oncology,Department of Pathology, Eastern Hepatobiliary Surgery Hospital,Second Military Medical University, Shanghai 200438, China.Expression of HBx protein in hepatitis B virus-infected intrahepatic cholangiocarcinoma[J].Hepatobiliary & Pancreatic Diseases International,2012,11(5):532-535. 被引量:9
  • 2胡志东,王金良.一种新的肿瘤标志物TU M2-PK的研究进展[J].国外医学(临床生物化学与检验学分册),2005,26(3):162-164. 被引量:15
  • 3彭宝岗,何强.不同部位胆管癌的临床病理特征和诊治进展[J].中国实用外科杂志,2007,27(5):414-416. 被引量:4
  • 4Kumar Y, Gurusamy K, Pamecha V, et al. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis[J].Pancreas, 2007, 35 (2): 114-119.
  • 5Hathurusinghe HR, GoonetiUeke KS, Siriwardena AK. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy[J].Ann Surg Oncol, 2007, 14(10):2714-2720.
  • 6Ugurel S, Bell N, Sucker A, et al. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma [J].IntJ Cancer, 2005, 117(5): 825-830.
  • 7Mazurek S, Grimm H, Boschek CB, et al. Pyruvate kinase type M2: a crossroad in the tumor metabolome[J]. BrJ Nutr, 2002, 87 Suppl 1: S23-S29.
  • 8Kaura B, Bagga R, Patel FD. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma[J].J Obstet Gynaecol Res, 2004, 30(3):193-196.
  • 9Weinberger R, Appel B, Stein A, et al. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour maa:ker for renal cell carcinoma[J].EurJ Cancer Care(Engl), 2007, 16(4): 333-337.
  • 10Lufmer D, Mazurek S, Henschke P, et al. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer[J].Anticancer Res, 2003, 23(2A): 991-997.

共引文献55

同被引文献90

引证文献11

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部